Halozyme Therapeutics, Inc. (NASDAQ:HALO) had its price objective lifted by equities research analysts at BMO Capital Markets from $14.00 to $15.00 in a report issued on Friday. The brokerage presently has a “market perform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target would indicate a potential downside of 6.19% from the stock’s current price.

HALO has been the topic of a number of other reports. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Friday, August 11th. BidaskClub upgraded shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Canaccord Genuity set a $16.00 price objective on shares of Halozyme Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 26th. ValuEngine upgraded shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Deutsche Bank AG increased their price objective on shares of Halozyme Therapeutics to $20.00 and gave the company a “buy” rating in a research note on Friday. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $16.00.

Shares of Halozyme Therapeutics (NASDAQ HALO) traded up 2.82% during midday trading on Friday, reaching $16.43. 3,458,980 shares of the company traded hands. Halozyme Therapeutics has a 12 month low of $8.18 and a 12 month high of $16.65. The firm’s market capitalization is $2.20 billion. The company has a 50 day moving average of $12.70 and a 200 day moving average of $13.21.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.02. The company had revenue of $33.80 million for the quarter, compared to the consensus estimate of $31.76 million. During the same quarter last year, the company earned ($0.21) earnings per share. The company’s revenue was up 1.2% compared to the same quarter last year. On average, equities research analysts predict that Halozyme Therapeutics will post ($0.88) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Halozyme Therapeutics, Inc. (HALO) Price Target Increased to $15.00 by Analysts at BMO Capital Markets” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/09/15/halozyme-therapeutics-inc-halo-price-target-increased-to-15-00-by-analysts-at-bmo-capital-markets.html.

Several large investors have recently modified their holdings of HALO. Wells Fargo & Company MN raised its holdings in shares of Halozyme Therapeutics by 22.5% during the first quarter. Wells Fargo & Company MN now owns 303,626 shares of the biopharmaceutical company’s stock worth $3,935,000 after purchasing an additional 55,719 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Halozyme Therapeutics by 27.3% during the first quarter. Bank of New York Mellon Corp now owns 1,806,490 shares of the biopharmaceutical company’s stock worth $23,412,000 after purchasing an additional 387,486 shares during the period. Karp Capital Management Corp acquired a new stake in shares of Halozyme Therapeutics during the first quarter worth $188,000. Sei Investments Co. raised its holdings in shares of Halozyme Therapeutics by 0.8% during the first quarter. Sei Investments Co. now owns 309,725 shares of the biopharmaceutical company’s stock worth $4,014,000 after purchasing an additional 2,605 shares during the period. Finally, Parametric Portfolio Associates LLC raised its holdings in shares of Halozyme Therapeutics by 37.2% during the first quarter. Parametric Portfolio Associates LLC now owns 52,784 shares of the biopharmaceutical company’s stock worth $684,000 after purchasing an additional 14,308 shares during the period. 85.08% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.